Navigation Links
Medivation's Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimer's Disease Patients, Resulting in Reduced Caregiver Distress
Date:3/15/2008

t the entire one-year treatment period. Significantly fewer serious adverse events were reported in the Dimebon group than in the placebo group at 12 months (p=0.03).

Medivation is planning to initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in mild-to-moderate Alzheimer's disease in the second quarter of 2008 with the goal of completing the trial and applying for U.S. and European marketing approval in 2010. The Company is also evaluating Dimebon in an ongoing Phase 2 clinical trial in mild-to-moderate Huntington's disease. Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's and Huntington's diseases, making it a potential treatment for these and other neurodegenerative diseases.

About Medivation

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three large, unmet medical needs -- Alzheimer's disease, Huntington's disease and hormone-refractory prostate cancer. The Company's strategy is to identify promising product candidates, to develop them in a rapid, cost-effective manner, and to seek development and/or commercialization partners as appropriate to complement its internal efforts. For more information, please go to http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding anticipated clinical and regulatory milestones, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. None of the Company's product candidates has been approved for sale, significan
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
3. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
4. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
5. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
6. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
7. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
11. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... OTTAWA , April 23, 2015 /CNW/ - Health ... oral ibuprofen products to update the safety information regarding ... attack and stroke) when these products are used at ... increases with dose and duration of use. ... pain and fever relief, and to reduce inflammation. The ...
(Date:4/23/2015)... Apr. 23, 2015 Surna, Inc. (OTCQB: SRNA), ... state-of-the art equipment and systems for controlled environment ... cannabis cultivation, will host a shareholder conference call ... 2015, at 4:15 PM Eastern Standard Time/1:15 PM ... call will be listen-in only, but will include ...
(Date:4/23/2015)... 23, 2015  Hill-Rom Holdings, Inc., (NYSE: HRC ... at the Deutsche Bank 40 th Annual Health ... EDT. You are invited to listen to ... http://ir.hill-rom.com/events.cfm or access it directly at http://edge.media-server.com/m/p/yvym8uoy ... available one hour after conclusion of the live event ...
Breaking Medicine Technology:Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 2Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 3Information Update - New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses 4Surna, Inc. Announces Shareholder Conference Call 2Surna, Inc. Announces Shareholder Conference Call 3
... PRINCETON, N.J., Feb. 1, 2011 Soligenix, Inc. (OTC ... Company), a late-stage biopharmaceutical company, announced today that it ... President and Chief Medical Officer. Dr. Horgan is a ... and experience in the care of patients with inflammatory ...
... AssureRx Health, Inc. today announced the appointments of two ... Donald R. Wright, Jr. has been appointed as executive ... Bellano as senior vice president, sales & commercial programs. ... of AssureRx,s pharmacogenetic test, GeneSightRx®, and the blueprint ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth 2AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth 3
(Date:4/24/2015)... Vancouver, BC (PRWEB) April 24, 2015 ... Albert Yuzpe, Olive Fertility co-founder and co-director, has been ... Fertility Preservation at the Evening of Hope Gala. ... to recognize Dr. Albert Yuzpe, who has been at ... past 43 years,” says Jessica Séguin, Executive Director of ...
(Date:4/24/2015)... April 24, 2015 National Access ... and legal access to medical cannabis, is taking a ... supported when advising patients. , NAC is the first ... With a $250,000 grant, NAC will be providing 300 ... "Our goal is to help Canadians gain safe and ...
(Date:4/24/2015)... April 24, 2015 Telematics Berlin is ... automakers, tier 1 & 2 suppliers, content providers, associations ... players in the value chain, see them converge in ... not only hear from those companies currently at the ... future partners. Working on customer centric products, ParkTAG are ...
(Date:4/24/2015)... PURE Solutions, a leader in allergy travel ... Network), a highly respected education, advocacy and community out-reach ... information for a special allergy travel section ... goal for both organizations is to “make lives better” ... with asthma and allergies and by finding effective ways ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 ProTube Outro is ... Pro X video editors. ProTube Outro allows editors to ... 5 video drop zones. Position, scale, and rotate pictures/videos, ... ProTube Outro uses simple borders and shadows for a ... exclusive plugin. , ProTube Outro comes packed with over 30 ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 2Health News:Telematics Berlin 2015’s inaugural European Automotive Start-Up Competition 3Health News:PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy Travel Tips 2Health News:Pixel Film Studios, FCPX Plugin Developer Announced the Release of Protube Outro, Outro Screen Templates for Final Cut Pro X 2
... sexually transmitted infections to tell their partners// to seek ... or drugs to help reduce infection rates, says a ... an important part of managing most curable sexually transmitted ... often makes this difficult. ,Researchers analysed ...
... is in the process of doing away with a commonly ... phase out the ‘Aropax’ brand of paroxetine and bring in ... used by about 49,000 New Zealanders. ,This move ... maintains that both drugs are the same, except for the ...
... supplements of folic acid could improve the memory and ... researchers from the University of Wageningen gave a group ... acid supplements or a dummy drug for three years, ... ,The folic acid group had significantly better memories and ...
... are helping to lead a large international study // ... in an effort to determine whether exercise really is ... promoted the value of exercise for a variety of ... established as safe in the group of patients who ...
... light of new information on facial transplantation—including the psychological ... of the Royal College of Surgeons of England now ... according to a report published in the Jan. 27 ... in 2003, the Working Party concluded that facial transplantation ...
... It’s no secret why we shed tears. But exactly what our ... ,A new study sheds some light on the complex design ... film, which is made up of three distinct, microscopic layers. The ... when we cry – is sandwiched between a layer of mucus ...
Cached Medicine News:Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Royal College Issues Revised Guidelines for Face Transplantation 2Health News:Royal College Issues Revised Guidelines for Face Transplantation 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: